RxDoctor Payments Data

Mohammad Madantschi, MD

Sleep Medicine · Phoenix, AZNPI 1710103023

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (47.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 70.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $5,811 and has fallen 94.3% since, to $333 in 2025.

$8,426in general payments, 2019–2025

Across 105 payments — averaging $80.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • AstraZeneca$631
  • Boehringer Ingelheim$416
  • United Therapeutics Corporation$277
  • GSK$229
  • Actelion Pharmaceuticals US, Inc.$201
  • plus $717 from 14 others

What the payments were for

  • Travel & lodging$96611%
  • Food & beverage$3,44641%
  • Education$4,00548%
  • Gifts$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,426 in reported general payments places this provider in the 80th percentile of 47 sleep medicine providers in Arizona.

See all sleep medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$103,237
Medicare patients
283
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$35,025
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$20,177
Spiriva RespimatTiotropium Bromide18$11,537
Breo ElliptaFluticasone/Vilanterol13$5,188
SymbicortBudesonide/Formoterol Fumarate17$4,864
Albuterol Sulfate HfaAlbuterol Sulfate114$3,306
Fluconazole31$1,358
Azithromycin66$579
Pantoprazole Sodium23$292
Montelukast Sodium46$281
Prednisone21$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$229$40,21452 claims
AstraZenecaBreztri Aerosphere, Symbicort$631$25,04045 claims
Boehringer IngelheimSpiriva Respimat$416$11,53718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 47 sleep medicine providers in Arizona.

Other sleep medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →